Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition characterized by phenotypic heterogeneity that could partly be explained by the variability in genetic variants contributing to disease. Accurate interpretation of these variants constitutes a major challenge for diagnosis and implementing precision medicine, especially in understudied populations. Here, we leverage ancestry-matched Egyptian patients (n=514) and deeply-phenotyped controls (n=400) to accurately define the genetic architecture of HCM. We also compare HCM variation between Egyptian and predominantly European patients to identify genetic features unique to consanguineous populations in Middle East and North Africa (MENA), which are likely to represent important contributors to disease. We report a higher prevalence of homozygous variants in Egyptian patients (4.1% vs 0.1%, p-value=2×10×7), with variants in the minor HCM genes MYL2, MYL3 and CSRP3 more likely to present in homozygosity than the major genes (MYH7, MYBPC3), suggesting that these variants are less penetrant in heterozygosity. Biallelic variants in the recessive HCM gene TRIM63 were detected in 2.1% of patients (5-fold greater than European patients), highlighting the importance of recessive inheritance/genes in consanguineous populations. Finally, significantly fewer rare variants detected in Egyptian HCM patients could be classified as (likely) pathogenic compared to Europeans (40.8% vs. 61.6%, p-value=1.6×10×5) due to the underrepresentation of MENA populations in current HCM databases. This proportion increased to 53.8% after incorporating methods that compare variant frequencies between Egyptian patients and controls. Together, our findings demonstrate that studying consanguineous populations reveals novel insights with relevance to genetic testing and our understanding of the genetic architecture of HCM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is part of the Egyptian Collaborative Cardiac Genomics Project. It was supported by the Science and Technology Development Fund government grant (Egypt), the Wellcome Trust (107469/Z/15/Z; 200990/A/16/Z), the Medical Research Council (United Kingdom), the NIHR Royal Brompton Cardiovascular Biomedical Research Unit, the NIHR Imperial College Biomedical Research Center, and a Health Innovation Challenge Fund award from the Wellcome Trust and Department of Health, United Kingdom (HICF/R6/373). Drs Allouba and Halawa were funded by Al Alfi Foundation to support their PhD degrees at Imperial College London and American University in Cairo, respectively. Dr Aguib is supported by Fondation Leducq (11 CVD/01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee 20130405MYFAHC_CMR of Aswan Heart Centre/Magdi Yacoub Foundation gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵12 Senior author
Data Availability
All data produced in the present work are contained in the manuscript
